Previous 10 | Next 10 |
REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Co...
C ombine s Codexis’ R&D and commercialization platform with Casdin Capital ’s investment expertise to invest in and support innovative early stage life science and synthetic biology technology compan...
The following slide deck was published by Codexis, Inc. in conjunction with this event. For further details see: Codexix (CDXS) Investor Presentation - Slideshow
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences: Stifel Healthcare Conference on Monday, November 16, 2020 wit...
Codexis, Inc. (CDXS) Q3 2020 Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Jody Cain - LHA John Nicols - President and CEO Ross Taylor - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Steph...
Codexis (CDXS): Q3 Non-GAAP EPS of -$0.06 misses by $0.01; GAAP EPS of -$0.10 beats by $0.02.Revenue of $18.4M (-16.0% Y/Y) beats by $2.49M.Press Release For further details see: Codexis EPS misses by $0.01, beats on revenue
Stronger than expected total revenues of $18.4 million delivered in the quarter Higher sequential sales expected again in the fourth quarter, showing growing momentum as we close 2020 Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif., Nov. 05, 2020 (G...
REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020. Codexis management will hold an investment commun...
REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences: H.C. Wainwright 22 nd Annual Global Investment Conference on Monday, Se...
In March, the coronavirus pandemic forced Codexis (NASDAQ: CDXS) to temporarily close its research facilities. Although the company began reopening in May and expects to be close to full operating capacity by the end of the summer, the coronavirus pandemic had a negative impact on the busine...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...